BioStem Technologies, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioStem Technologies, Inc. (OTC: BSEM) BioStem Technologies, Inc. is a regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies. The company produces innovative perinatal tissue-based products using its proprietary BioREtain processing method, which preserves the tissue's natural growth factors, cytokines, extracellular matrix, and structural integrity while adhering to AATB-accredited, FDA-registered, and cGMP-compliant standards; its core portfolio includes membrane allografts such as VENDAJE, VENDAJE AC, VENDAJE OPTIC, AmnioWrap2, American Amnion, and American AC, designed as protective coverings for soft tissue wounds including diabetic foot ulcers, venous stasis ulcers, and surgical applications, with additional offerings in biologic stem cell alternatives for joint pain, tendon and ligament injuries, neurodegenerative and autoimmune diseases, as well as nutraceuticals under the Dr. Dave’s Best and Nesvik Organics brands sold via e-commerce. Founded in 2014 and headquartered in Pompano Beach, Florida, BioStem Technologies operates primarily in the United States with international nutraceutical distribution and targets clinicians, hospitals, and patients in wound care and orthopedics. In recent developments, the company signed a letter of intent in November 2024 to acquire FDA 510(k)-cleared wound care products ProgenaMatrix—a human keratin matrix—and revyve Antimicrobial Wound Gel from ProgenaCare Global to expand its hospital-based portfolio and treatment continuum; it purchased a four-acre land parcel in Boca Raton's Research Park at Florida Atlantic University in November 2025 for a new $49.5 million headquarters, manufacturing, and distribution facility, planning to create 100 high-paying jobs; and expanded product access in Medicaid markets while reporting third-quarter 2025 financial results and restating prior statements for 2023 through mid-2025.
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
BioStem Technologies Q1 Earnings Call Highlights
BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates
BioStem Technologies Reports First Quarter 2026 Financial Results
BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026
BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025
BioStem Technologies Q4 Earnings Call Highlights
BioStem Technologies, Inc. (BSEM) Q4 2025 Earnings Call Transcript
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026
Head to Head Analysis: Cardiff Oncology (NASDAQ:CRDF) and BioStem Technologies (OTCMKTS:BSEM)